Biogen (NASDAQ: BIIB) shares were upgraded to Buy from Hold, with the price target raised to $299 from $223 per ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE